Moreover, midostaurin inhibits c-Kit (wild type and D816V mutant) found in advanced systemic mastocytosis (SM), which includes aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), and mast cell leukemia [55]. This evidence concerns the gene KIT and systemic mastocytosis.